EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach
Science Advances · 2026
DOI: 10.1126/sciadv.aee5560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Misbah Aziz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Endothelial-Mesenchymal Transition, Atherosclerosis, Epigenesis, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Heart Foundation of Australia.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Atherosclerosis drives cardiovascular morbidity in diabetes, with endothelial-to-mesenchymal transition (EndMT) as a key contributor. Whereas epigenetic regulators are increasingly implicated in atherosclerotic progression, the specific role of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, in EndMT in diabetes-associated atherosclerosis remains unclear. We show that EZH2-mediated H3K27 (histone H3 at lysine-27) trimethylation is elevated in carotid plaques from patients with diabetes and in the aortic endothelium of diabetic Apoe −/− mice. Pharmacologic EZH2 inhibition with GSK-126 attenuated EndMT and reduced atherosclerotic burden in diabetic mice. In human aortic endothelial cells exposed to high glucose/tumor necrosis factor–α or serum from patients with coronary artery disease, EZH2 blockade via GSK-126 or short hairpin RNA suppressed EndMT and reversed transcriptional programs assessed by RNA sequencing, including COL4A1 and NR2F2 . These findings identify EZH2 as a driver of EndMT in diabetes-associated atherosclerosis and highlight EZH2 inhibition as a potential therapeutic strategy to limit vascular pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
- Diabetes Institute, Division of Metabolism, Endocrinology, and Diabetes, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
- Baker Heart and Diabetes Institute, Melbourne, Australia.
- Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research, Heinrich Heine University Dusseldorf, Dusseldorf, Germany.
ORCID-Profile: Misbah Aziz, Jairo A Pinzon-Cortes, Aozhi Dai, Scott Maxwell, Jun Okabe, Mark E Cooper, Abdul Waheed Khan
Förderung
- National Heart Foundation of Australia
Zitieren
APA
Aziz, M., Sourris, K. C., Pinzon-Cortes, J. A., Block, T. J., Dai, A., Maxwell, S., Okabe, J., Calkin, A. C., Cooper, M. E., Jandeleit-Dahm, K. A. M., & Khan, A. W. (2026). EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach. Science Advances. https://doi.org/10.1126/sciadv.aee5560
Vancouver
Aziz M, Sourris KC, Pinzon-Cortes JA, Block TJ, Dai A, Maxwell S, et al. EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach. Science Advances. 2026. doi:10.1126/sciadv.aee5560
BibTeX
@article{Aziz2026,
author = {Aziz, Misbah and Sourris, Karly C and Pinzon-Cortes, Jairo A and Block, Tomasz J and Dai, Aozhi and Maxwell, Scott and Okabe, Jun and Calkin, Anna C and Cooper, Mark E and Jandeleit-Dahm, Karin A M and Khan, Abdul Waheed},
title = {EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aee5560}
}
EUVIMED